...
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Cerebral Venous Sinus Thrombosis and Acute Myocardial Infarction in a Patient with PAI-1 4G/4G Homozygosity
【24h】

Cerebral Venous Sinus Thrombosis and Acute Myocardial Infarction in a Patient with PAI-1 4G/4G Homozygosity

机译:PAI-1 4g / 4g纯合子患者中脑静脉血栓形成和急性心肌梗死

获取原文
获取原文并翻译 | 示例
           

摘要

The plasminogen activator inhibitor-1 (PAI-1) 4G/4G homozygous genotype represents a genetic thrombophilia that has been associated with enhanced risk of arterial and venous thrombotic events. The optimal anticoagulation strategy for PAI-1 4G homozygous patients is unclear. Herein we present a case of a patient with PAI-1 4G/4G homozygosity who was placed on dabigatran after developing cerebral venous sinus thrombosis (CVST), but who then suffered an acute myocardial infarction several weeks later. We seek to highlight the relationship between the PAI-1 4G/4G genotype and risk of CVST, as well as discuss our management strategy in the aftermath of dabigatran failure.
机译:纤溶酶原激活物抑制剂-1(PAI-1)4G/4G纯合基因型代表一种遗传性血栓形成倾向,与动脉和静脉血栓形成事件的风险增加有关。PAI-1 4G纯合子患者的最佳抗凝策略尚不清楚。我们在此报告一例PAI-1 4G/4G纯合子患者,在发生脑静脉窦血栓形成(CVST)后服用达比加群,但几周后发生急性心肌梗死。我们试图强调PAI-1 4G/4G基因型与CVST风险之间的关系,并讨论达比加群失败后的管理策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号